These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 15669896)

  • 21. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donepezil in treatment-resistant bipolar disorder.
    Burt T; Sachs GS; Demopulos C
    Biol Psychiatry; 1999 Apr; 45(8):959-64. PubMed ID: 10386177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donepezil in schizophrenia--is it helpful? An experimental design case study.
    MacEwan GW; Ehmann TS; Khanbhai I; Wrixon C
    Acta Psychiatr Scand; 2001 Dec; 104(6):469-72. PubMed ID: 11782241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects.
    Kim JH; Byun HJ
    Clin Neuropharmacol; 2003; 26(6):312-6. PubMed ID: 14646611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394.
    Lohr JB; Caligiuri MP; Edson R; Lavori P; Adler LA; Rotrosen J; Hitzemann R
    J Clin Psychopharmacol; 2002 Apr; 22(2):196-200. PubMed ID: 11910266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
    Cummings JL; McRae T; Zhang R;
    Am J Geriatr Psychiatry; 2006 Jul; 14(7):605-12. PubMed ID: 16816014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Donepezil and tardive dyskinesia.
    Schopick D
    J Am Acad Child Adolesc Psychiatry; 2005 Feb; 44(2):112. PubMed ID: 15689723
    [No Abstract]   [Full Text] [Related]  

  • 33. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes: A Naturalistic Observational Study in Patients With Psychotic Disorders.
    Lee D; Baek JH; Bae M; Choi Y; Hong KS
    J Clin Psychopharmacol; 2019; 39(6):591-596. PubMed ID: 31688397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease.
    Bergman J; Lerner V
    Clin Neuropharmacol; 2002; 25(2):107-10. PubMed ID: 11981238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
    Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
    J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.
    Brar JS; Parepally H; Chalasani L; Gopalani A; Appel N; Chengappa KN
    Ann Clin Psychiatry; 2008; 20(3):139-44. PubMed ID: 18633740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
    Risch SC; Horner MD; McGurk SR; Palecko S; Markowitz JS; Nahas Z; DeVane CL
    Schizophr Res; 2007 Jul; 93(1-3):131-5. PubMed ID: 17391930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.